AXIM (AXIM Biotechnologies) EBIT: $0.22 Mil (TTM As of Jun. 2025)


What is AXIM Biotechnologies EBIT?

AXIM Biotechnologies AXIM -16.00% EBIT is $0.22 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

AXIM Biotechnologies's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was $0.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $0.22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AXIM Biotechnologies's annualized ROC % for the quarter that ended in Jun. 2025 was -1.13%. AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 684.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AXIM Biotechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 2.45%.

AXIM Biotechnologies  (OTCPK:AXIM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AXIM Biotechnologies's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-0.088 * ( 1 - 0% )/( (8.031 + 7.573)/ 2 )
=-0.088/7.802
=-1.13 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.346 - 1.984 - ( 0.007 - max(0, 6.677 - 0.008+0.007))
=8.031

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.224 - 1.854 - ( 0.003 - max(0, 6.206 - 0.003+0.003))
=7.573

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.524/( ( (0.227 + max(-6.599, 0)) + (0.218 + max(-6.104, 0)) )/ 2 )
=1.524/( ( 0.227 + 0.218 )/ 2 )
=1.524/0.2225
=684.94 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.001 + 0) - (1.984 + 0.499 + 4.117)
=-6.599

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.854 + 0.01 + 4.24)
=-6.104

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AXIM Biotechnologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=0.22/8.973
=2.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies EBIT Related Terms

AXIM Biotechnologies EBIT Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies EBIT Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.97 -15.54 -4.37 -6.86 -2.88

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -2.03 0.00 -0.16 0.38

AXIM vs HEPA, SCNI, BZYR: EBIT Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's EV-to-EBIT falls into.


AXIM Biotechnologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $0.22 Mil mean?
AXIM Biotechnologies (AXIM) has a EBIT of $0.22 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AXIM Biotechnologies.
Is AXIM Biotechnologies' EBIT too high?
AXIM Biotechnologies' current EBIT is $0.22 Mil.
How does AXIM Biotechnologies' EBIT compare to HEPA and SCNI?
AXIM Biotechnologies' EBIT of $0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AXIM Biotechnologies. AXIM Biotechnologies's current EBIT is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current EBIT of $0.22 Mil. The current EBIT is $0.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current EBIT is $0.22 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.